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Abstract 
BACKGROUNDː Dysglycemia is associated with adverse outcome including increased morbidity and 
mortality in surgical patients. Acute insulin resistance due to the surgical stress response is seen as a 
major cause of so-called stress hyperglycemia. However, understanding of factors determining blood 
glucose (BG) during surgery is limited. Therefore, we investigated risk factors contributing to 
intraoperative dysglycemia. 
METHODSː In this subgroup investigation of the BIOCOG study, we analyzed 87 patients of ≥ 65 years 
with tight intraoperative BG measurement every 20 min during elective surgery. Dysglycemia was defined 
as at least one intraoperative BG measurement outside the recommended target range of 80-150 mg/dL. 
Additionally, all postoperative BG measurements in the ICU were obtained. Multivariable logistic 
regression analysis adjusted for age, sex, American Society of Anesthesiologists (ASA) status, diabetes, 
type and duration of surgery, minimum Hemoglobin (Hb) and mean intraoperative norepinephrine use 
was performed to identify risk factors of intraoperative dysglycemia. 
RESULTSː 46 (52.9%) out of 87 patients developed intraoperative dysglycemia. 31.8% of all intraoperative 
BG measurements were detected outside the target range. Diabetes [OR 9.263 (95% CI 2.492, 34.433); 
p=0.001] and duration of surgery [OR 1.005 (1.000, 1.010); p=0.036] were independently associated with 
the development of intraoperative dysglycemia. Patients who experienced intraoperative dysglycemia had 
significantly elevated postoperative mean (p<0.001) and maximum BG levels (p=0.001). Length of ICU 
(p=0.007) as well as hospital stay (p=0.012) were longer in patients with dysglycemia.  
CONCLUSIONSː Diabetes and duration of surgery were confirmed as independent risk factors for 
intraoperative dysglycemia, which was associated with adverse outcome. These patients, therefore, might 
require intensified glycemic control. Increased awareness and management of intraoperative dysglycemia 
is warranted. 
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Introduction 
Perioperative dysglycemia is frequently seen 
and associated with postoperative morbidity and 
mortality [1-3]. Impaired immune function, increased 
risk of postoperative infections, acute kidney injury, 
delayed wound healing, postoperative delirium and 
impaired cognition are recognized as adverse 
outcomes related to intraoperative hyperglycemia 
[3-10]. Hypoglycemia is known to contribute to poor 
postoperative outcome including cardiac 








stay and overall mortality, as well [11-13]. Acute 
insulin resistance is seen as a major cause of 
intraoperative hyperglycemia due to the surgical 
stress response enhancing the release of 
catecholamines and cortisol [14, 15], which can result 
in so-called stress hyperglycemia [16]. Associated 
increased glucose variability induces oxidative stress 
and may also negatively impact patients’ recovery [17, 
18]. Intraoperative hypoglycemia frequently occurs in 
response to intensified insulin therapy (IIT). 
Accordingly, IIT protocols during surgery have 
produced different results on clinical outcome: While 
Gandhi et al. [19] and Saager et al. [20] found 
increased incidences of stroke and delirium; Kwon et 
al. [21] demonstrated reduced infection and mortality 
rates. 
In fact, evidence suggests that glucose variability 
resulting in both hyper- and hypoglycemia rather 
than either hyper- and hypoglycemia alone is critical 
to clinical outcome, at least in ICU patients [22, 23]. 
Targeting glucose levels reduced morbidity and 
mortality from sepsis in critically ill patients as 
reported by van den Berghe et al. [24]. Despite the 
recognition of adverse outcome associated with 
dysglycemia, understanding of underlying causes of 
intraoperative dysglycemia is limited. In this 
subgroup investigation of the BIOCOG study, we 
aimed to identify risk factors contributing to 
intraoperative dysglycemia to describe potential 
causes for glycemic derangement during surgery.  
Materials and methods 
Study population 
This subgroup investigation of the Biomarker 
Development for Postoperative Cognitive Impairment 
in the Elderly (BIOCOG) study (ethics EA2/092/14, 
clinicaltrials.gov: NCT02265263, www.biocog.eu) 
aimed to investigate risk factors of intraoperative 
dysglycemia in non-cardiac elderly patients. The 
BIOCOG study is a prospective multicenter 
observational study to develop biomarkers for risk 
prediction of postoperative cognitive impairment by 
assessment of parameters such as clinical, molecular 
and imaging data [25]. Patients were eligible if at least 
65 years of age and if anticipated time of surgery was 
≥ 60 min. Patients with a preexisting diagnosis of 
diabetes as well as non-diabetic patients were 
included. For the purpose of this subgroup 
investigation, a subgroup (“SugarCog”) of 89 patients 
enrolled at the site Charité – Universitätsmedizin 
Berlin between February and December 2016 obtained 
tight intraoperative blood glucose (BG) measurements 
every 20 min. These patients were preoperatively 
planned to receive an arterial catheter for clinical 
reasons such as anticipated high blood loss or need 
for continuous monitoring of blood pressure. All 
patients received guideline-based anesthesiological 
and surgical treatment according to our standard 
operating procedures (SOP) [26].  
The objective of the study was to identify risk 
factors for intraoperative dysglycemia. In addition, 
we investigated the association of intraoperative and 
postoperative dysglycemia, the association of 
intraoperative dysglycemia on postoperative 
outcome, and whether time-out-of-target-range rather 
than maximum levels are associated with 
postoperative mortality. 
Measurement of intraoperative blood glucose 
levels 
BG levels were intraoperatively measured 
immediately after establishment of an arterial catheter 
after anesthesia induction and then regularly every 20 
min until extubation. BG levels measured until up to 1 
hour after extubation were considered as 
intraoperative data. If the patient was not extubated 
immediately after surgery, BG levels were measured 
until the patient was transferred to the ICU. All 
arterial blood gas analyses (ABG) were performed by 
ABL800 FLEX Radiometer. Dysglycemia was defined 
according to our SOP as BG levels outside the 
recommended target range of 80-150 mg/dL [26]. 
Patients were subsequently categorized into 
normoglycemia (80-150 mg/dL) and dysglycemia (at 
least one intraoperative measurement outside the 
target range). Minimum, mean and maximum BG 
levels were determined. Glycemic variability was 
calculated as the standard deviation of all available 
intraoperative measurements. Additionally, we 
determined minutes out of target range from begin 
until end of surgery. 
Determination of postoperative blood glucose 
levels  
Postoperative BG levels were abstracted from 
patients’ electronic ICU charts. We included ICU 
measurements only as BG was assessed at regular 
time intervals as opposed to non-ICU-patients where 
BG assessment was performed infrequently and at 
irregular intervals. The same criteria as for 
intraoperative dysglycemia were applied to all 
postoperative BG measurements.  
Perioperative inflammatory markers 
C-reactive protein (CRP) levels obtained within 
clinical routine were abstracted from patients´ charts. 
CRP values preoperatively and on postoperative day 
1 were compared to investigate a relationship 
between the inflammatory state and dysglycemia. 




Clinical outcome parameters 
Postoperative complications were documented 
up to hospital discharge and retrospectively classified 
according to the Clavien-Dindo classification [27]. For 
further analyses, we considered Clavien-Dindo grade 
I-II as minor and grade ≥III as major complications 
[28]. Length of ICU stay, time until hospital discharge 
and 90-day mortality were obtained. 
Statistical analysis 
Results are expressed as median (25%; 75% 
quartiles), or n frequencies (%), respectively. 
Differences between groups were tested using 
non-parametric exact Mann-Whitney-U test for 
continuous parameters and exact Chi-Square-test for 
qualitative data. To quantify surgical 
time-out-of-target range, we calculated the ratio of 
time outside the target range from begin until end of 
surgery. Multivariable logistic regression analysis was 
performed to identify factors associated with 
intraoperative dysglycemia. Age, sex, American 
Society of Anesthesiologists (ASA) status (II versus 
≥III), diabetes, type (intra-abdominal/-thoracic versus 
other) and duration of surgery, minimum 
intraoperative hemoglobin (Hb) as well as mean rate 
of norepinephrine over anesthesia time were entered 
into the final model. A detailed list of types of 
surgeries depicts Supplement Table S1. Odds ratios 
(OR) with 95%-confidence intervals (CI) and the 
corresponding p-values were calculated for each risk 
factor. In a post-hoc approach, the most predictive 
time point for dysglycemia to occur was determined 
by a receiver operating characteristics (ROC) curve. 
Between-group differences regarding postoperative 
glycemic profiles and clinical outcome were assessed 
by univariate testing, i.e. exact non-parametric 
Mann-Whitney-U test and exact Chi-Square-test, 
respectively. In addition, using the exact 
Mann-Whitney-U test, maximum BG levels and 
time-out-of-target range were compared between 
survivors and non-survivors 90 days after surgery, in 
order to test for differences in intraoperative 
dysglycemia. 
For the purpose of this exploratory subgroup 
investigation, no a priori sample size calculation was 
performed. All results have to be understood in the 
area of purely exploratory data analysis. No 
adjustments for multiple testing have been made and 
p-values do not allow for confirmatory generalization 
of results. A two-tailed p-value <0.05 was considered 
statistically significant. Analyses were carried out 
using IBM© SPSS© Statistics (version 25) and The R 
Project for Statistical Computing (version 3.4.1). 
Ethics 
Ethical approval was obtained 
(Ethikkommission der Charité – Universitätsmedizin 
Berlin, EA2/092/14). All patients gave written 
informed consent upon enrolment. The study 
complied with the Declaration of Helsinki. 
Results 
Study population 
Of 89 patients included in this subgroup 
investigation, 87 had a prospectively investigated 
tight intraoperative BG measurement and were, thus, 
included in the final analysis (Figure 1). Of these, 58 
also had at least one postoperative BG measurement 
by clinical staff due to admission to the ICU. All 
patients received general anesthesia. One patient 
required mechanical ventilation due to hypothermia 
after the end of surgery and was extubated in the ICU 
5 hours later. All other patients were extubated 
immediately after end of surgery. 1354 BG levels were 
intraoperatively measured [15 (9; 21) per patient]. 
31.8% of all measured BG levels were outside the 
target range of 80-150 mg/dL (Figure 2). 1309 BG 
levels were postoperatively obtained [13 (6; 28) per 
patient]. Over all patients, intraoperative minimum 
and maximum BG was 64 mg/dL and 325 mg/dL, 
respectively. Postoperatively, minimum and 
maximum BG was 53 mg/dL and 357 mg/dL, 
respectively. 
Intraoperative dysglycemia occurred in 46 out of 
87 patients (52.9%). Table 1 demonstrates the 
distribution of patient baseline characteristics, intra- 
and postoperative variables between patients with 
intraoperative dysglycemia and those within target 
range. Patients with dysglycemia had significantly 
more often a primary diagnosis of diabetes mellitus 
and had a longer duration of surgery.  
Risk factors for intraoperative dysglycemia 
Adjusting for age, sex, ASA status, diabetes, type 
and duration of surgery, minimum Hb as well as 
intraoperative mean rate of norepinephrine over 
anesthesia time, multivariable logistic regression 
revealed only diabetes and duration of surgery as 
independently associated with dysglycemia (Table 2). 
In a post-hoc approach, plotting of the ROC curve 
revealed a surgical time of 134 min most predictive for 
dysglycemia to occur (sensitivity 71.7%, specificity 
63.4%, AUC 0.678, p=0.004). Course of intraoperative 
BG levels between diabetic and non-diabetic patients 
is shown in Figure 3. 
 




Patients with intraoperative dysglycemia 
showed increased postoperative maximum 
glucose levels 
High incidences of postoperative dysglycemia 
were seen in both groups (Table 3). Patients with 
intraoperative dysglycemia showed increased 
postoperative maximum (p=0.001) and mean BG 
levels (p<0.001). Postoperative dysglycemia occurred 
in 18 patients (46.2%) who experienced intraoperative 




Figure 1. Consort diagram. 
 
 
Figure 2. Histogram of all 1354 intraoperative blood glucose measurements. 





Figure 3. Time course of intraoperative blood glucose levels between diabetic and non-diabetic patients. Eleven out of 27 (40.7%) diabetic patients received 
intraoperative insulin (median 8 IU (4; 18)) while 7 out of 60 (11.7%) non-diabetic patients were treated with intraoperative insulin (median 12 IU (4; 14)). For reasons 
of comparability between diabetic and non-diabetic patients, measurements exceeding 300 min are not shown to maintain > 5 measurements per group. First time 
point was measured immediately after anesthesia induction when the arterial catheter was established. Plotted curves indicate median BG values; grey bands reflect 
95% confidence intervals of the respective group. 
 
Table 1.Study population and characteristics. 
 Total Sample (n = 87) Dysglycemia (n = 46) Target range (n = 41) p value 
Baseline Characteristics 
Age, years 74 (69; 77) 72 (69; 23) 75 (71; 78) 0.286* 
Sex, male n (%) 42 (48.3%) 20 (43.5%) 22 (53.7%) 0.394† 
BMI, kg/m² 27 (23; 30) 26 (23; 29) 27 (23; 30) 0.971* 
ASA status, n (%)    0.522† 
    ASA II 43 (49.4%) 21 (45.7%) 22 (53.7%)  
    ASA III 44 (50.6%) 25 (54.3%) 19 (46.3%)  
Charlson Comorbidity Index 2 (2; 3) 3 (2; 4) 2 (2; 3) 0.163* 
Malignancy, n (%) 61 (70.1%) 34 (73.9%) 27 (65.9%) 0.485† 
Diabetes mellitus, n (%) 27 (31.0%) 21 (45.7%) 6 (14.6%) 0.002† 
Preoperative HbA1C, % 5.7 (5.2; 6.0) 5.9 (5.2; 6.8) 5.5 (5.2; 5.9) 0.025* 
Insulin, n (%) 18 (20.7%) 17 (37.0%) 1 (2.4%) <0.001† 
Metformin, n (%) 8 (9.2%) 5 (10.9%) 3 (7.3%) 0.717† 
Steroids, n (%) 5 (5.7%) 2 (4.3%) 3 (7.3%) 0.663† 
CRP 5.7 (2.7; 20.8) 8.4 (3.0; 23.3) 5.1 (2.3; 17.2) 0.577* 
ADL 100 (95; 100) 100 (95; 100) 100 (95; 100) 0.985* 
IADL 8 (8; 8) 8 (8; 8) 8 (8; 8) 0.368* 
Intraoperative Characteristics 
Type of surgery    0.056† 
    Intra-abdominal/-thoracic, n (%) 70 (80.5%) 41 (89.1%) 29 (70.7%)  




    Other, n (%) 17 (19.5%) 5 (10.9%) 12 (29.3%)  
Duration of surgery, min 233 (131; 360) 280 (178; 401) 166 (120; 303) 0.004* 
Glucose < 80mg/dL, n (%) 2 (2.3%) 2 (4.3%) 0  0.496† 
Glucose > 150mg/dL, n (%) 45 (51.7%) 45 (97.8%) 0  <0.001† 
Glucose out of target range, minutes 0 (0; 132) 118 (65; 244) 0 <0.001* 
Proportion (%) of time-out-of-target range 0 (0; 66) 60 (26; 91) 0  <0.001* 
Glucose minimum, mg/dL 109 (96; 125) 124 (103; 140) 102 (93; 113) <0.001* 
Glucose mean, mg/dL 131 (117; 184) 152 (138; 172) 117 (108; 127) <0.001* 
Glucose maximum, mg/dL 153 (133; 184) 182 (158; 206) 133 (119; 144) <0.001* 
Glucose variability, mg/dL  13 (7; 18) 16 (13; 23) 8 (5; 12) <0.001* 
Insulin, n (%) 
Insulin, IU 
18 (20.7%) 
10 (4; 15) 
17 (37.0%) 
10 (4; 13) 
1 (2.4%) 
30 (30; 30) 
<0.001† 
0.111* 
PRBC, mL 0 (0; 310) 0 (0; 620) 0 (0; 155) 0.092* 
FFP, mL 0 (0; 1320) 110 (0; 1980) 0 (0; 330) 0.007* 
Hb minimum, g/dL 9.3 (8.1; 11.4) 9.1 (7.9; 10.9) 9.6 (8.5; 11.9) 0.110* 
Norepinephrine mean rate over anesthesia time, µg/kg/min 0.07 (0.03; 0.09) 0.07 (0.03; 0.10) 0.05 (0.03; 0.07) 0.029* 
Epidural catheter, n (%) 45 (51.7%) 27 (58.7%) 18 (43.9%) 0.201† 
Postoperative Characteristics  
CRP POD1 86.9 (42.9; 118.5) 75.3 (43.5; 140.9) 88.7 (40.8; 100.8) 0.885* 
Clavien-Dindo, n (%)    0.123† 
    Minor  48 (55.2%) 23 (50.0%) 25 (61.0%)  
    Major 35 (40.2%) 23 (50.0%) 12 (29.3%)  
LOS ICU, h  23 (0; 110) 45 (18; 211) 20 (0; 46) 0.007* 
LOS, d 9 (6; 20) 14 (8; 25) 8 (5; 13) 0.012* 
90d mortality, n (%) 16 (18.4%) 10 (21.7%) 6 (14.6%)  0.422† 
Data are shown as median with quartiles (25%; 75%) or as frequencies n (%). P values are calculated using the exact Chi Square test† or exact Mann-Whitney-U test*, 
respectively. 
ADL: Activities of Daily Living; ASA: American Society of Anesthesiologists; BMI: Body Mass Index, CCI: Charlson Comorbidity Index; CRP: C-reactive protein; FFP: Fresh Frozen Plasma; 
Hb: Hemoglobin; IADL: Instrumental Activities of Daily Living; ICU: Intensive Care Unit; LOS: Length of Stay; POD: Postoperative day; PRBC: Packed red blood cells 
 
Table 2. Risk factors for intraoperative dysglycemia. 
Predictors Odds Ratio (95% CI) p value 
Age 0.974 (0.883, 1.075) 0.600 
Sex (male) 0.511 (0.174, 1.503) 0.223 
ASA status 1.599 (0.513, 4.979) 0.418 
Diabetes 9.263 (2.492, 34.433) 0.001 
Intra-abdominal/-thoracic surgery 4.863 (0.926, 25.532) 0.062 
Duration of surgery 1.005 (1.000, 1.010) 0.036 
Hb, minimum 1.187 (0.821, 1.716) 0.363 
Norepinephrine, mean rate 
(µg/kg/min) 
118 767.902 (0.072,  
196 869 515 621.882) 
0.110 
ASA: American Society of Anesthesiologists; Hb min: Hemoglobin, minimum 
intraoperative concentration  
Multivariate logistic regression with intraoperative dysglycemia as response was 
performed with age, sex, ASA status, diabetes, type and duration of surgery, 
minimum hemoglobin and intraoperative mean rate of norepinephrine over 
anesthesia time as covariates. 
Table 3. Postoperative glycemic profile between patients with 
and without intraoperative dysglycemia. 
 Dysglycemia  
(n = 39) 
Target range  
(n = 19) 
p value 
Glucose minimum, mg/dL 102 (88; 126) 93 (83; 105) 0.117* 
Glucose mean, mg/dL 142 (131; 165) 123 (115; 136) <0.001* 
Glucose maximum, mg/dL 198 (170; 225) 165 (147; 180) 0.001* 
Postoperative dysglycemia, n (%)  34 (87.2%) 14 (73.7%) 0.270† 
Diabetes, n (%) 17 (43.6%) 1 (5.3%) 0.003* 
HbA1c (%) 5.8 (5.2; 6.7) 5.2 (5.1; 6.0) 0.085* 
Data are shown as median with quartiles (25%; 75%) or as frequencies n (%). P 
values are calculated using the exact Chi Square test† and the exact 
Mann-Whitney-U test*, respectively. 
 
Intraoperative dysglycemia was associated 
with adverse clinical outcome 
No differences were seen in terms of 
postoperative complications with regard to 
Clavien-Dindo classification (Table 1). However, 
dysglycemic patients had a significantly longer ICU 
(p=0.007) as well as hospital LOS (p=0.012). When 
differentiating between patients with and without 
preexisting diabetes, those who experienced 
dysglycemia without diabetes (n=25) showed a trend 
towards higher mortality rates compared to patients 
with both diabetes and intraoperative dysglycemia 
(n=21) [deceased 8 (32.0%) versus 2 (9.5%); p=0.084)]. 
Discussion 
This study is the first to investigate risk factors 
for the development of intraoperative dysglycemia in 
a mixed surgical cohort. The primary finding of this 
study is that diabetes and duration of surgery were 
associated with intraoperative dysglycemia 
independent of age, sex, ASA status, type of surgery, 
minimum Hb and mean norepinephrine rate over 
anesthesia time. A surgical time of at least 134 min 
was most predictive for developing intraoperative 
dysglycemia. Furthermore, dysglycemic patients were 
at higher risk for postoperative hyperglycemia and 
adverse postoperative outcome. Importantly, only 
two patients experienced hypoglycemia whereas 
hyperglycemia was detected in 45 patients including 
one with both hypo- and hyperglycemia. 
Consequently, hyper- rather than hypoglycemia 
challenges intraoperative BG management. However, 
both require attention as hypoglycemia might ensue 
from overtreatment of hyperglycemia. 
To the moment, extent rather than duration of 
surgery has been considered a major contributor to 




perioperative hyperglycemia [10]. Clarke et al. [29] 
found major surgery to be associated with more 
severe dysglycemia reasoning that extended surgical 
trauma leads to increased inflammation and 
subsequently to a more pronounced stress response. 
However, our results indicate that duration rather 
than the extent of surgery contributes to dysglycemia, 
suggesting that surgical time is critical to progress of 
the inflammatory response. Subsequently, insulin 
resistance in response to surgical stress and its related 
inflammatory process might be aggravated over time, 
thereby underscoring the key role of time in the 
development of dysglycemic states. 
Even though intraoperative dysglycemia likely 
occurred in response to inflammatory stress, no 
difference between patients with dysglycemia and 
those without was seen in CRP levels neither 
preoperatively nor 1 day after surgery. As 
demonstrated by Thorell et al. [30], cytokine release, 
as one component of the surgical stress response, is 
related to reduced insulin sensitivity. The authors 
reported a relationship between increased IL-6 
plasma concentrations and a decrease in insulin 
sensitivity. However, those findings were limited to 
the postoperative period. Yet, others detected an IL-6 
increase early during surgery suggesting that IL-6 
mediated insulin resistance increases BG levels over 
time [31]. This holds important implications for 
intraoperative BG management. Strategies to control 
the inflammatory stress response might be considered 
in order to reduce stress hyperglycemia. Although no 
difference with regard to dysglycemia was seen in our 
cohort between patients with and without epidural 
anesthesia, its use has been demonstrated to reduce 
the neuroendocrine stress response [32]. An effect 
similar to that of dexmedetomidine was shown by 
Shamim et al. [33]. They reported an attenuated stress 
response in patients receiving dexmedetomidine 
during laparascopic pyeloplasty. Patients treated with 
dexmedetomidine had significantly lower levels of 
serum cortisol and BG. Besides measures to prevent 
intraoperative hyperglycemia, monitoring its 
development is of particular concern. Given that the 
development of dysglycemia is related to surgical 
time, intensified glycemic control is justified with 
increasing length of surgery. Anesthesiologists should 
be aware of the increased risk for dysglycemia 
suggesting intensified BG monitoring, at least in 
increased surgical time. Detecting dysglycemia at an 
early time point allows for adequate therapy. Since 
dysglycemia is an adverse event for which treatment 
is easily available, i.e. administering of either insulin 
or glucose, prevention by thorough monitoring 
should be the objective of intraoperative BG 
management. 
In our analysis, the critical time for dysglycemia 
to occur was after 134 minutes. Of note, 31.8% of all 
BG measurements lay outside the target range. 
Although BG was monitored closely in this cohort 
and appropriate therapy was available, glucose 
concentrations outside the target range remained 
high. These findings point out an underestimation of 
intraoperative dysglycemia. Therefore, close BG 
measurement needs to be included into clinical 
routine while dysglycemia should be treated 
immediately.  
Patients with a known diagnosis of diabetes 
were at higher risk to develop intraoperative 
dysglycemia. It is acknowledged that diabetic patients 
demonstrate higher BG levels intraoperatively [34]. 
Yet, Masla et al. [35] found no difference in 
intraoperative BG levels between diabetic and 
non-diabetic patients undergoing coronary artery 
bypass grafting (CABG). However, this might be due 
to the fact that the authors assessed BG every 30 
minutes only during bypass time. Alterations in BG 
during on-pump CABG might differ from those 
occurring during non-cardiac surgery.  
Diabetic patients are less likely to experience 
adverse postoperative outcome compared to 
non-diabetic patients with dysglycemia [2, 36]. This 
might reflect adaption to higher BG levels in that 
diabetic patients can cope inflammatory and oxidative 
stress [2, 37]. In consequence, different BG target 
ranges might be recommended for patients with 
diabetes while patients without diabetes benefit from 
early intervention to prevent damage from acute 
hyperglycemia [37]. The fact that intraoperative 
dysglycemia was related to elevated BG maximum 
levels in the postoperative period indicates that 
intraoperatively acquired imbalances influence 
metabolic homeostasis after surgery. These findings 
suggest that intraoperative stress hyperglycemia 
might persist in the postoperative period also in 
non-diabetic patients. Nair et al. [38] reported similar 
findings showing that intraoperative elevated mean 
glucose levels were associated with elevated 
postoperative levels. Consequently, it can be assumed 
that intraoperatively dysglycemic patients are at high 
risk to develop hyperglycemia postoperatively. The 
recognition that dysglycemia developing 
intraoperatively is related to postoperative 
hyperglycemia which itself is a predictor for increased 
morbidity and mortality, warrants preventive 
strategies for dysglycemia. Furthermore, in patients 
with dysglycemia, tight glycemic control should be 
maintained during the postoperative period to avoid 
adverse outcomes [21, 39]. In future studies, it will 
also be of interest to investigate whether a history of 
dysglycemia related to surgery in non-diabetic 




patients is associated with an increased risk to 
develop diabetes mellitus. 
In the clinical context of surgical ICU patients, it 
has been acknowledged that targeting BG levels 
within a prespecified range improves clinical outcome 
[24, 40]. However, data on the impact of 
intraoperative glycemic control and the association of 
intraoperative and postoperative dysglycemia in 
non-cardiac patients remain scarce [38]. Gandhi et al. 
identified intraoperative hyperglycemia as a predictor 
for adverse outcome including increased mortality 
after cardiac surgery [41]. A trial conducted by the 
same research group investigating the influence of 
intraoperative insulin therapy revealed no reduction 
in postoperative morbidity but rather an increase of 
death and stroke related to tight glycemic control, 
which was attributed to hypoglycemia after insulin 
therapy [19]. These findings contrast those of Bláha et 
al. [34] who reported a reduction in postoperative 
complications when comparing intraoperative tight 
glucose control to postoperative initiation supporting 
the concept of glucose target control. 
In our study population of 87 patients, 
dysglycemia was seen in 46 (52.9%) patients of which 
21 (45.7%) had a known diagnosis of diabetes 
indicating that in more than 50% of all cases, 
dysglycemia developed in patients without a 
previous diagnosis of diabetes, which is well 
described as stress hyperglycemia [16]. In previous 
studies, differences occurred in patients with diabetes 
and those without, although both experience an 
increase in glucose levels in response to surgical stress 
[42]. However, stress hyperglycemia in non-diabetics 
leads to a relatively higher rise in BG levels affecting 
coagulation and immune function and increasing the 
risk for adverse cardiovascular events [5, 43, 44]. 
Consequently, in the critically ill without known 
diabetes, hyperglycemia has deleterious effects on 
outcome including survival, whereas patients with 
diabetes seem to be less affected [45, 46]. This is 
consistent with our finding: Non-diabetics with 
dysglycemia showed increased 90-day mortality. 
These protective effects of chronic hyperglycemia on 
acute hyperglycemia have been attributed to a 
downregulation of glucose transporters protecting 
tissues from glucose toxicity [37]. Langouche et al. 
demonstrated reduced inflammatory activation of the 
endothelium as a result of insulin therapy providing a 
rationale for insulin administration to maintain 
euglycemia [47]. Yet, complete understanding of the 
pathophysiology of stress hyperglycemia requires 
further investigation. 
Since dysglycemia can be diagnosed during 
surgery, and should, thus, be preventable if 
recognized in time, a concept of a standardized 
protocol for intraoperative glycemic control is 
warranted. However, in order to target intraoperative 
BG levels, the underlying factors of dysglycemia need 
to be identified. We hereby hope to contribute to a 
better understanding of the development of 
dysglycemia. 
This study has obvious limitations. First, our 
sample size of 87 patients aged ≥ 65 years limits 
generalizability to different patient groups. Second, 
we did not assess insulin resistance nor was 
continuous glucose monitoring available. Particularly 
insulin resistance as underlying pathophysiology 
might be of great interest in further studies. Third, 
total blood loss was not assessed and could not be 
adjusted for in regression analysis. Given that blood 
loss may also indicate surgical stress, BG levels could 
also have been influenced. Fourth, no marker 
indicating intraoperative inflammation was available 
to support the pathobiology of prolonged 
inflammation leading to the development of 
dysglycemia. Only CRP measurements were obtained 
pre- and postoperatively which are insufficient to 
assess the inflammatory response in the perioperative 
period. Finally, survival data were only obtained until 
day 90 after surgery limiting long-term follow-up. 
Conclusions 
The duration of surgery and preexisting diabetes 
were confirmed as independent risk factors for the 
occurrence of intraoperative dysglycemia, while age, 
sex, ASA status, type of surgery, minimum Hb and 
norepinephrine had no influence. These patients were 
also at risk for severe postoperative hyperglycemia 
and adverse outcome. Further studies are warranted 
to identify preventive strategies such as tight glycemic 
control. 
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